预约演示
Insilico teams up with Menarini for breast cancer KAT6 inhibitor
临床1期引进/卖出
The standard of care for ER+/HER2- breast cancers is endocrine treatments, that may eventually stop working. Credit: Anchiy via Getty Images.
Insilico Medicine has joiER+/HER2- breast cancers through its subsidiary Stemline Therapeutics to develop a small molecule KAT6A inhibitor to treat hormone-sensitive cancers, focusing on ER+/HER2- breast cancer.
Insilico Medicine involves an exclusive lMenariniMenarini agreement, providing StStemline Therapeuticsghts to develop and commerciaKAT6A inhibitorKAT6Aa novel KAT6A inhibihormone-sensitive cancersing Insilico’sER+/HER2- breast cancere (AI) platform.
The molecule has shown positive results in preclinical studies, demonstStemline potent inhibition in multiple CDX and PDX models, as welKAT6A inhibitorKAT6Aa good safety and efficacy profile. Insilico presented data on this development at the San Antonio Breast Cancer Symposium last month.
Insilico will receive $12m in an upfront payment from Menarini, as well as milestone payments with a combined value of more than $500m and sales royalties.Breast Cancer
In the announcementInsiliconying the agreement, Menarini CEO Elcin Barker Ergun said: “Having brought the first innovaWuXi AppTecocrine therapy after almost 20 years to the US and Europe with elacestrant for ER+/HER2- breast cancer patients, our aim is to further augment patient outcomes, and targeting KAT6A can potentially serve that in breast cancer and beyond.”
KAT6A proteins play a crucial role in regulatingMenarinipression and are implicated in various cancers, including poor clinical outcomes of ER+/HER- breast cancers.elacestrantER+/HER2- breast cancerKAT6Abreast cancer
Other companies are also looking at the same protein inhibition. Pfizer’s PF-07248144 is under cancersment for the treatment of locally advaER+/HER- breast cancersHER2- breast cancer, metastatic castration-resistant prostate cancer and metastatic non-small cell lung cancer (NSCLC).
According to GlobalData’s Pharmaceutical Intelligence Center, PF-Pfizer44 PF-07248144y being investigated in a Phase I clinical trial, with a Phase II trial plER+/HER2- breast cancermetastatic castration-resistant prostate cancermetastatic non-small cell lung cancer (NSCLC)
GlobalData is the parent company of Pharmaceutical Technology.PF-07248144
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。